Dr Pardoll speaks with ecancer at AACR 2018 about outcomes from a trial of 20 patients who received anti-PD1 nivolumab before surgical resection.

Pathological responses were observed in 45% of patients and, at a median follow-up of 12 months, 16 patients remain recurrence free.

Dr Pardoll discusses the staging and followup of this trial group, and its prospects for further investigation.

Sign up to ecancer for free to receive tailored email alerts for more videos like this.

[ Ссылка ]

свернуть